Here, the PROTAC function is activated in a biomarker-dependent fashion, which ensures the degradation of the targeted BCL2 protein selectively in the cancer cells.430 This approach highlights an entirely new strategy, in which PROTACs may be more selectively delivered to the intended cell types. This evidence concerns the gene BCL2 and cancer.